ProfileGDS5678 / 1434383_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 91% 91% 89% 89% 90% 89% 90% 91% 92% 92% 92% 91% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5023292
GSM967853U87-EV human glioblastoma xenograft - Control 27.382791
GSM967854U87-EV human glioblastoma xenograft - Control 37.4678291
GSM967855U87-EV human glioblastoma xenograft - Control 47.2866589
GSM967856U87-EV human glioblastoma xenograft - Control 57.1441689
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.0330590
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.865889
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1856290
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.268891
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.6727392
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6197392
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6738492
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.389391
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5579792